Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Sales 2023 | -3.62K -3.9K | Sales 2024 * | - | Capitalization | 19.84M 21.35M |
---|---|---|---|---|---|
Net income 2023 | -28M -30.13M | Net income 2024 * | -18M -19.37M | EV / Sales 2023 | -53,497 x |
Net cash position 2023 | 18.52M 19.93M | Net cash position 2024 * | 19.55M 21.04M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.06
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
Latest transcript on Vivoryon Therapeutics AG
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |